The high price of cancer drugs in the US relative to European countries with universal health care raises ethical issues of access, financial burden on patients, and unsustainability of the health care system.
AMA J Ethics. 2015;17(8):750-753. doi:
10.1001/journalofethics.2015.17.8.nlit1-1508.
Similar key outcomes in patients from hospitals where financial incentives were offered and patients from hospitals where financial incentives were not offered suggest that financial incentives may not be the answer to improving quality of care.